KR100473824B1 - 상피종의진단및치료방법 - Google Patents

상피종의진단및치료방법 Download PDF

Info

Publication number
KR100473824B1
KR100473824B1 KR10-1998-0704242A KR19980704242A KR100473824B1 KR 100473824 B1 KR100473824 B1 KR 100473824B1 KR 19980704242 A KR19980704242 A KR 19980704242A KR 100473824 B1 KR100473824 B1 KR 100473824B1
Authority
KR
South Korea
Prior art keywords
antibody
biwa
antibodies
molecule
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR10-1998-0704242A
Other languages
English (en)
Korean (ko)
Other versions
KR19990071952A (ko
Inventor
칼-하인쯔 하이더
귄터 아돌프
엘린보르그 오스테르만
에릭 패트젤트
마르리에스 스프롤
Original Assignee
베링거 인겔하임 인터내셔날 게엠베하
포르슝스첸트룸 칼스루에 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19545472A external-priority patent/DE19545472A1/de
Application filed by 베링거 인겔하임 인터내셔날 게엠베하, 포르슝스첸트룸 칼스루에 게엠베하 filed Critical 베링거 인겔하임 인터내셔날 게엠베하
Publication of KR19990071952A publication Critical patent/KR19990071952A/ko
Application granted granted Critical
Publication of KR100473824B1 publication Critical patent/KR100473824B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G01N33/575—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70585—CD44
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR10-1998-0704242A 1995-12-06 1996-12-05 상피종의진단및치료방법 Expired - Fee Related KR100473824B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19545472.3 1995-12-06
DE19545472A DE19545472A1 (de) 1995-12-06 1995-12-06 Verfahren zur Diagnose und Therapie von Plattenepithelkarzinomen
DE19615074.4 1996-04-17
DE19615074 1996-04-17

Publications (2)

Publication Number Publication Date
KR19990071952A KR19990071952A (ko) 1999-09-27
KR100473824B1 true KR100473824B1 (ko) 2005-09-30

Family

ID=26020988

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-1998-0704242A Expired - Fee Related KR100473824B1 (ko) 1995-12-06 1996-12-05 상피종의진단및치료방법

Country Status (25)

Country Link
EP (1) EP0865609B1 (enExample)
JP (1) JP2000502067A (enExample)
KR (1) KR100473824B1 (enExample)
CN (1) CN1151377C (enExample)
AR (1) AR004360A1 (enExample)
AT (1) ATE235056T1 (enExample)
AU (1) AU726704B2 (enExample)
BG (1) BG62985B1 (enExample)
BR (1) BR9611901A (enExample)
CA (1) CA2239709A1 (enExample)
CO (1) CO4520233A1 (enExample)
CZ (1) CZ174198A3 (enExample)
DE (1) DE59610248D1 (enExample)
DK (1) DK0865609T3 (enExample)
EE (1) EE03783B1 (enExample)
ES (1) ES2190484T3 (enExample)
MX (1) MX9804459A (enExample)
NO (1) NO319903B1 (enExample)
NZ (1) NZ324314A (enExample)
PL (1) PL184521B1 (enExample)
PT (1) PT865609E (enExample)
SK (1) SK284378B6 (enExample)
TR (1) TR199801027T2 (enExample)
UY (1) UY24389A1 (enExample)
WO (1) WO1997021104A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7947496B2 (en) * 1999-10-08 2011-05-24 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7189397B2 (en) * 1999-10-08 2007-03-13 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US20050100542A1 (en) * 1999-10-08 2005-05-12 Young David S. Cytotoxicity mediation of cells evidencing surface expression of CD44
US20030103985A1 (en) 2001-05-18 2003-06-05 Boehringer Ingelheim International Gmbh Cytotoxic CD44 antibody immunoconjugates
EP1258255A1 (en) * 2001-05-18 2002-11-20 Boehringer Ingelheim International GmbH Conjugates of an antibody to CD44 and a maytansinoid
CN1541226A (zh) * 2001-05-18 2004-10-27 ���ָ��Ӣ��ķ�������Ϲ�˾ CD44v6特异性的抗体
US6972324B2 (en) 2001-05-18 2005-12-06 Boehringer Ingelheim Pharmaceuticals, Inc. Antibodies specific for CD44v6
EP1391213A1 (en) * 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
EP1417974A1 (en) * 2002-11-08 2004-05-12 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and radiotherapy
JP5763105B2 (ja) * 2010-02-04 2015-08-12 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 頭頸部扁平上皮癌の治療に使用されるｃｄ４４に対するモノクローナル抗体
US9218450B2 (en) 2012-11-29 2015-12-22 Roche Molecular Systems, Inc. Accurate and fast mapping of reads to genome
EP3755717A4 (en) * 2018-02-22 2022-01-26 Multitude Inc. THERAPEUTIC ANTIBODY AND USES THEREOF
IL317000A (en) 2022-05-25 2025-01-01 Akiram Therapeutics Ab Antibodies against CD44V6 and their use in the treatment of cancers that overexpress CD44V6

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69406664T2 (de) * 1993-06-18 1998-06-04 Biotie Therapies Oy Zusammensetzungen und diagnostische verfahren unter verwendung von monoklonalen antikoerpern gegen cd44v6
WO1995000851A1 (de) * 1993-06-22 1995-01-05 Boehringer Ingelheim International Gmbh Verfahren zur diagnose und analyse von tumoren
DE4326573A1 (de) * 1993-08-07 1995-02-23 Boehringer Ingelheim Int Durch Exon v5 des CD44-Gens kodierte Polypeptide als Targets für Immuntherapie und Immunszintigraphie von Tumoren
UA58482C2 (uk) * 1994-06-08 2003-08-15 Бьорінгер Інгельхайм Інтернаціональ Гмбх Моноклональне антитіло vff-18 проти сd44v6 і його фрагменти

Also Published As

Publication number Publication date
NO319903B1 (no) 2005-09-26
KR19990071952A (ko) 1999-09-27
MX9804459A (es) 1998-09-30
JP2000502067A (ja) 2000-02-22
EE03783B1 (et) 2002-06-17
CZ174198A3 (cs) 1999-02-17
EE9800164A (et) 1998-12-15
DE59610248D1 (de) 2003-04-24
UY24389A1 (es) 2001-10-25
AR004360A1 (es) 1998-11-04
BR9611901A (pt) 1999-03-02
CA2239709A1 (en) 1997-06-12
SK284378B6 (sk) 2005-02-04
NO982588D0 (no) 1998-06-05
PL327066A1 (en) 1998-11-23
ATE235056T1 (de) 2003-04-15
CN1151377C (zh) 2004-05-26
NZ324314A (en) 2000-02-28
HK1011560A1 (en) 1999-07-16
EP0865609A1 (de) 1998-09-23
DK0865609T3 (da) 2003-06-23
AU1177397A (en) 1997-06-27
BG62985B1 (bg) 2000-12-29
AU726704B2 (en) 2000-11-16
PT865609E (pt) 2003-08-29
NO982588L (no) 1998-08-05
ES2190484T3 (es) 2003-08-01
CN1207811A (zh) 1999-02-10
SK73698A3 (en) 1999-01-11
BG102513A (en) 1999-02-26
TR199801027T2 (xx) 1998-10-21
WO1997021104A1 (de) 1997-06-12
CO4520233A1 (es) 1997-10-15
PL184521B1 (pl) 2002-11-29
EP0865609B1 (de) 2003-03-19

Similar Documents

Publication Publication Date Title
EP1470146B1 (en) Antibodies against the muc18 antigen
CN113321731B (zh) 结合人程序性死亡配体1(pd-l1)的抗体
EP1467757B1 (en) Use of antibodies against the muc18 antigen
US5489525A (en) Monoclonal antibodies to prostate cells
US9193794B2 (en) Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same
KR100379217B1 (ko) CD44v6에대한모노클로날항체
JP2005538682A (ja) カルボキシックアンヒドラーゼｉｘ（ｃａｉｘ）腫瘍抗原に対する抗体
JP2005516965A (ja) 抗ｍｕｃ１８抗体を使用する方法
KR100473824B1 (ko) 상피종의진단및치료방법
EP3543259A2 (en) Antibody binding to carbonic anhydrase and use thereof
CN115297890A (zh) 用于对患癌的对象处置癌的抗meflin抗体和含有该抗体的药物组合物
JP6758388B2 (ja) 抗−ｃｄ４３抗体およびその癌治療用途
EP3387016A1 (en) Antibodies for treatment and diagnosis of inflammatory bowel disease
US10975160B2 (en) Antibody binding to carbonic anhydrase and use thereof
KR20090130335A (ko) 암 세포 세포독성을 매개하는 인간화 및 키메라 항-ｃｄ５９ 항체
JP2001508052A (ja) ホジキンリンパ腫（Ｈｏｄｇｋｉｎ’ｓ ｌｙｍｐｈｏｍａ）の診断および治療方法
RU2193779C2 (ru) Средство и способ лечения плоскоклеточного рака
RU2735102C1 (ru) Антитело, специфично связывающееся с белком PAUF, и его применение
HK1011560B (en) Method of diagnosing and treating epithelioma
HK1011697B (en) Monoclonal antibody active against cd44v6
HK40025609B (en) Antibody specifically binding to pauf protein and use thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20080219

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20080219

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000